Precision pharmacotherapy: Psychiatry’s future direction in preventing, diagnosing, and treating mental disorders

Pharmacogenomics and Personalized Medicine

Volumn 11, Issue , 2018, Pages 211-222

  Menke, Andreas ^a,b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Biomarker; Childhood trauma; Depression; FKBP5; Machine learning; Mental health; Personalized medicine; Precision medicine

Indexed keywords

ANTIDEPRESSANT AGENT;

ABCB1 GENE; ARTIFICIAL INTELLIGENCE; ATTENTION DEFICIT DISORDER; DEEP LEARNING; ELECTRONIC HEALTH RECORD; ENVIRONMENTAL FACTOR; FKBP5 GENE; GENE; GENE EXPRESSION; GENETIC SCREENING; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE ENVIRONMENT INTERACTION; HEALTHY LIFESTYLE; HEREDITY; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LIFESTYLE; MACHINE LEARNING; MAJOR DEPRESSION; MEDICAL ERROR; MENTAL DISEASE; NEUROPSYCHOLOGICAL TEST; NUTRITION; PERSONALIZED MEDICINE; POSTTRAUMATIC STRESS DISORDER; PSYCHIATRY; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; SPORT; STRESS;

EID: 85062807993     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S146110     Document Type: Review

References (168)

1. Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psychiatr Soc. 2009;18(1):23–33.
2. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–679.
3. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe – a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol. 2005;15(4):357–376.
4. Institute of Medicine (US) Committee on Pathophysiology and Prevention of Adolescent and Adult Suicide. Reducing Suicide: A National Imperative. Goldsmith SK, Pellmar TC, Kleinman AM, Bunney WE, editors. Washington (DC): National Academies Press (US);
5. Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature. 2011;475(7354):27–30.
6. Stephan KE, Bach DR, Fletcher PC, et al. Charting the landscape of priority problems in psychiatry, part 1: classification and diagnosis. Lancet Psychiatry. 2016;3(1):77–83.
7. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013;11(1):126.
8. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167(7):748–751.
9. Mcmahon FJ. Prediction of treatment outcomes in psychiatry – where do we stand? Dialogues Clin Neurosci. 2014;16(4):455–464.
10. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med Overseas Ed. 2015;372(9):793–795.
11. Jameson JL, Longo D. Precision medicine – personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229–2234.
12. Perlis RH. Abandoning personalization to get to precision in the pharmacotherapy of depression. World Psychiatry. 2016;15(3): 228–235.
13. Holsboer F. How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci. 2008;9(8):638–646.
14. Insel TR, Scolnick EM. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry. 2006;11(1):11–17.
15. Wium-Andersen IK, Vinberg M, Kessing LV, McIntyre RS. Personalized medicine in psychiatry. Nord J Psychiatry. 2017;71(1):12–19.
16. Topol EJ. Individualized medicine from prewomb to tomb. Cell. 2014;157(1):241–253.
17. Sullivan PF, Agrawal A, Bulik CM, et al. Psychiatric genomics: an update and an agenda. Am J Psychiatry. 2018;175(1):15–27.
18. Sullivan PF, Daly MJ, O’Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet. 2012;13(8):537–551.
19. Smoller JW, Andreassen OA, Edenberg HJ, Faraone SV, Glatt SJ, Kendler KS. Psychiatric genetics and the structure of psychopathology. Mol Psychiatry. Epub 2018 Jan 9.
20. Maher B. Personal genomes: the case of the missing heritability. Nature. 2008;456(7218):18–21.
21. Corvin A, Craddock N, Sullivan PF. Genome-wide association studies: a primer. Psychol Med. 2010;40(7):1063–1077.
22. Altshuler D, Daly M. Guilt beyond a reasonable doubt. Nat Genet. 2007;39(7):813–815.
23. Mccarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet. 2008;9(5):356–369.
24. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, Ripke S, Wray NR, et al. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry. 2013;18(4):497–511.
25. Hek K, Demirkan A, Lahti J, et al. A genome-wide association study of depressive symptoms. Biol Psychiatry. 2013;73(7):667–678.
26. Hyde CL, Nagle MW, Tian C, et al. Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. Nat Genet. 2016;48(9):1031–1036.
27. Wray NR, Ripke S, Mattheisen M, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018;50(5):668–681.
28. Ripke S, Sanders AR, Kendler KS, Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011;43(10):969–976.
29. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–427.
30. Breen G, Li Q, Roth BL, et al. Translating genome-wide association findings into new therapeutics for psychiatry. Nat Neurosci. 2016;19(11):1392–1396.
31. Nelson MR, Tipney H, Painter JL, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47(8): 856–860.
32. Mangravite LM, Medina MW, Cui J, et al. Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Arterioscler Thromb Vasc Biol. 2010;30(7):1485–1492.
33. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009;41(1):56–65.
34. Brainstorm Consortium, Anttila V, Bulik-Sullivan B, et al. Analysis of shared heritability in common disorders of the brain. Science. 2018;360(6395):eaap8757.
35. Gandal MJ, Haney JR, Parikshak NN, et al. Shared molecular neu-ropathology across major psychiatric disorders parallels polygenic overlap. Science. 2018;359(6376):693–697.
36. Klengel T, Binder EB. Epigenetics of stress-related psychiatric disorders and gene × environment interactions. Neuron. 2015;86(6):1343–1357.
37. Binder EB. Dissecting the molecular mechanisms of gene × environment interactions: implications for diagnosis and treatment of stress-related psychiatric disorders. Eur J Psychotraumatol. 2017;8(Suppl 5):1412745.
38. Kendler KS, Davis CG, Kessler RC. The familial aggregation of common psychiatric and substance use disorders in the National Comorbidity Survey: a family history study. Br J Psychiatry. 1997;170(6): 541–548.
39. Kessler RC, Davis CG, Kendler KS. Childhood adversity and adult psychiatric disorder in the US National Comorbidity Survey. Psychol Med. 1997;27(5):1101–1119.
40. Heim C, Nemeroff CB. The role of childhood trauma in the neurobiol-ogy of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry. 2001;49(12):1023–1039.
41. Matosin N, Halldorsdottir T, Binder EB. Understanding the molecular mechanisms underpinning gene by environment interactions in psychiatric disorders: The FKBP5 Model. Biol Psychiatry. 2018;83(10):821–830.
42. Danese A, J Lewis S. Psychoneuroimmunology of early-life stress: the hidden wounds of childhood trauma? Neuropsychopharmacology. 2017;42(1):99–114.
43. Kuhlman KR, Chiang JJ, Horn S, Bower JE. Developmental psycho-neuroendocrine and psychoneuroimmune pathways from childhood adversity to disease. Neurosci Biobehav Rev. 2017;80:166–184.
44. Nusslock R, Miller GE. Early-life adversity and physical and emotional health across the lifespan: a neuroimmune network hypothesis. Biol Psychiatry. 2016;80(1):23–32.
45. Danese A, Pariante CM, Caspi A, Taylor A, Poulton R. Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci U S A. 2007;104(4):1319–1324.
46. Kirschbaum C, Pirke KM, Hellhammer DH. The ‘Trier Social Stress Test’ – a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology. 1993;28(1–2):76–81.
47. Pace TW, Mletzko TC, Alagbe O, et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry. 2006;163(9):1630–1633.
48. Carpenter LL, Gawuga CE, Tyrka AR, Lee JK, Anderson GM, Price LH. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology. 2010;35(13):2617–2623.
49. Leistner C, Menke A. How to measure glucocorticoid receptor’s sensitivity in patients with stress-related psychiatric disorders. Psychoneuroendocrinology. 2018;91:235–260.
50. Menke A, Lehrieder D, Fietz J, et al. Childhood trauma dependent anxious depression sensitizes HPA axis function. Psychoneuroendocrinology. 2018;98:22–29.
51. Uher R, Tansey KE, Dew T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014;171(12):1278–1286.
52. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31–41.
53. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12):1381–1391.
54. Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. 2018;23(2):335–343.
55. de Kloet ER, Joëls M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci. 2005;6(6):463–475.
56. Menke A, Binder EB. Epigenetic alterations in depression and antidepressant treatment. Dialogues Clin Neurosci. 2014;16(3):395–404.
57. Menke A, Klengel T, Binder EB. Epigenetics, depression and antidepressant treatment. Curr Pharm Des. 2012;18(36):5879–5889.
58. Dwivedi Y. Emerging role of microRNAs in major depressive disorder: diagnosis and therapeutic implications. Dialogues Clin Neurosci. 2014;16(1):43–61.
59. Geaghan M, Cairns MJ. MicroRNA and posttranscriptional dysregulation in psychiatry. Biol Psychiatry. 2015;78(4):231–239.
60. Binder EB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology. 2009;34(Suppl 1):S186–S195.
61. Binder EB, Salyakina D, Lichtner P, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004;36(12): 1319–1325.
62. Menke A, Klengel T, Rubel J, et al. Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav. 2013;12(3):289–296.
63. Klengel T, Mehta D, Anacker C, et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci. 2013;16(1):33–41.
64. Grabe HJ, Wittfeld K, Van der Auwera S, et al. Effect of the interaction between childhood abuse and rs1360780 of the FKBP5 gene on gray matter volume in a general population sample. Hum Brain Mapp. 2016;37(4):1602–1613.
65. Han KM, Won E, Sim Y, et al. Influence of FKBP5 polymorphism and DNA methylation on structural changes of the brain in major depressive disorder. Sci Rep. 2017;7(1):42621.
66. Tozzi L, Farrell C, Booij L, et al. Epigenetic changes of FKBP5 as a link connecting genetic and environmental risk factors with structural and functional brain changes in major depression. Neuropsychopharmacology. 2018;43(5):1138–1145.
67. Lovallo WR, Enoch MA, Acheson A, et al. Early-life adversity interacts with FKBP5 genotypes: altered working memory and cardiac stress reactivity in the Oklahoma Family Health Patterns Project. Neuropsychopharmacology. 2016;41(7):1724–1732.
68. Gopalakrishnan R, Kozany C, Gaali S, et al. Evaluation of synthetic FK506 analogues as ligands for the FK506-binding proteins 51 and 52. J Med Chem. 2012;55(9):4114–4122.
69. Gopalakrishnan R, Kozany C, Wang Y, et al. Exploration of pipecolate sulfonamides as binders of the FK506-binding proteins 51 and 52. J Med Chem. 2012;55(9):4123–4131.
70. Menke A, Arloth J, Best J, et al. Time-dependent effects of dexamethasone plasma concentrations on glucocorticoid receptor challenge tests. Psychoneuroendocrinology. 2016;69:161–171.
71. Menke A, Arloth J, Gerber M, et al. Dexamethasone stimulated gene expression in peripheral blood indicates glucocorticoid-receptor hypersensitivity in job-related exhaustion. Psychoneuroendocrinology. 2014;44:35–46.
72. Menke A, Arloth J, Pütz B, et al. Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients. Neuropsychopharmacology. 2012;37(6):1455–1464.
73. Cohen S, Janicki-Deverts D, Miller GE. Psychological stress and disease. JAMA. 2007;298(14):1685–1687.
74. Wilbert-Lampen U, Leistner D, Greven S, et al. Cardiovascular events during World Cup Soccer. N Engl J Med Overseas Ed. 2008;358(5): 475–483.
75. Arango C, Díaz-Caneja CM, McGorry PD, et al. Preventive strategies for mental health. Lancet Psychiatry. 2018;5(7):591–604.
76. van den Bosch M, Ode Sang Å. Urban natural environments as nature-based solutions for improved public health – a systematic review of reviews. Environ Res. 2017;158:373–384.
77. Morita E, Fukuda S, Nagano J, et al. Psychological effects of forest environments on healthy adults: Shinrin-yoku (forest-air bathing, walking) as a possible method of stress reduction. Public Health. 2007;121(1):54–63.
78. Ideno Y, Hayashi K, Abe Y, et al. Blood pressure-lowering effect of Shinrin-yoku (Forest bathing): a systematic review and meta-analysis. BMC Complement Altern Med. 2017;17(1):409.
79. Song C, Ikei H, Miyazaki Y. Physiological effects of nature therapy: a review of the research in Japan. Int J Environ Res Public Health. 2016;13(8):781.
80. Jacka FN, Mykletun A, Berk M. Moving towards a population health approach to the primary prevention of common mental disorders. BMC Med. 2012;10(1):149.
81. Jacka FN, Pasco JA, Mykletun A, et al. Association of Western and traditional diets with depression and anxiety in women. Am J Psychiatry. 2010;167(3):305–311.
82. Lai JS, Hiles S, Bisquera A, Hure AJ, Mcevoy M, Attia J. A systematic review and meta-analysis of dietary patterns and depression in community-dwelling adults. Am J Clin Nutr. 2014;99(1):181–197.
83. O’Neil A, Quirk SE, Housden S, et al. Relationship between diet and mental health in children and adolescents: a systematic review. Am J Public Health. 2014;104(10):e31–e42.
84. Sarris J, Logan AC, Akbaraly TN, et al. Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry. 2015;2(3):271–274.
85. Saunders EF, Ramsden CE, Sherazy MS, Gelenberg AJ, Davis JM, Rapoport SI. Reconsidering dietary polyunsaturated fatty acids in bipolar disorder: a translational picture. J Clin Psychiatry. 2016;77(10):e1342–e1347.
86. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Markers of gluten sensitivity in acute mania: a longitudinal study. Psychiatry Res. 2012;196(1):68–71.
87. Brown NC, Andreazza AC, Young LT. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res. 2014;218(1–2):61–68.
88. Severance EG, Tveiten D, Lindström LH, Yolken RH, Reichelt KL. The gut microbiota and the emergence of autoimmunity: relevance to major psychiatric disorders. Curr Pharm Des. 2016;22(40):6076–6086.
89. Willett WC, Sacks F, Trichopoulou A, et al. Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr. 1995;61(6 Suppl):S1402–S1406.
90. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med Overseas Ed. 2018; 378(25):e34.
91. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr. 2010;92(5): 1189–1196.
92. Psaltopoulou T, Sergentanis TN, Panagiotakos DB, Sergentanis IN, Kosti R, Scarmeas N. Mediterranean diet, stroke, cognitive impairment, and depression: a meta-analysis. Ann Neurol. 2013;74(4):580–591.
93. Grosso G, Micek A, Marventano S, et al. Dietary n-3 PUFA, fish consumption and depression: a systematic review and meta-analysis of observational studies. J Affect Disord. 2016;205:269–281.
94. Mocking RJ, Harmsen I, Assies J, Koeter MW, Ruhé HG, Schene AH. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry. 2016;6(3):e756.
95. Jacka FN, O’Neil A, Opie R, et al. A randomised controlled trial of dietary improvement for adults with major depression (the ‘SMILES’ trial). BMC Med. 2017;15(1):23.
96. Khambadkone SG, Cordner ZA, Dickerson F, et al. Nitrated meat products are associated with mania in humans and altered behavior and brain gene expression in rats. Mol Psychiatry. Epub 2018 Jul 18.
97. Hallgren M, Herring MP, Owen N, et al. Exercise, physical activity, and sedentary behavior in the treatment of depression: broadening the scientific perspectives and clinical opportunities. Front Psychiatry. 2016;7(1):36.
98. Pedersen BK, Saltin B. Exercise as medicine-evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports. 2015;25(Suppl 3):1–72.
99. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry. 2000;48(8):740–754.
100. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008;88(4): 1379–1406.
101. Pedersen BK, Pedersen M, Krabbe KS, Bruunsgaard H, Matthews VB, Febbraio MA. Role of exercise-induced brain-derived neurotrophic factor production in the regulation of energy homeostasis in mammals. Exp Physiol. 2009;94(12):1153–1160.
102. Roshanaei-Moghaddam B, Katon WJ, Russo J. The longitudinal effects of depression on physical activity. Gen Hosp Psychiatry. 2009;31(4):306–315.
103. Conn VS. Depressive symptom outcomes of physical activity interventions: meta-analysis findings. Ann Behav Med. 2010;39(2):128–138.
104. Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO. Exercise treatment for depression: efficacy and dose response. Am J Prev Med. 2005;28(1):1–8.
105. Bartley CA, Hay M, Bloch MH. Meta-analysis: aerobic exercise for the treatment of anxiety disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:34–39.
106. Firth J, Cotter J, Elliott R, French P, Yung AR. A systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol Med. 2015;45(7):1343–1361.
107. Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database Syst Rev. 2015;(4):CD006489.
108. Busch Y, Menke A. Blood-based biomarkers predicting response to antidepressants. J Neural Transm. Epub 2018 Jan 27.
109. Ising M, Lucae S, Binder EB, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009;66(9):966–975.
110. Tansey KE, Guipponi M, Hu X, et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry. 2013;73(7):679–682.
111. Arranz MJ, Rivera M, Munro JC. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs. 2011;25(11):933–969.
112. Fabbri C, Porcelli S, Serretti A. From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. Can J Psychiatry. 2014;59(2):62–75.
113. Brandl EJ, Kennedy JL, Müller DJ. Pharmacogenetics of antipsychotics. Can J Psychiatry. 2014;59(2):76–88.
114. Serretti A. The present and future of precision medicine in psychiatry: focus on clinical psychopharmacology of antidepressants. Clin Psychopharmacol Neurosci. 2018;16(1):1–6.
115. Fabbri C, Hosak L, Mössner R, et al. Consensus paper of the WFSBP Task Force on Genetics: genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. World J Biol Psychiatry. 2017;18(1):5–28.
116. Bousman CA, Hopwood M. Commercial phar macogenetic-based decision-support tools in psychiatry. Lancet Psychiatry. 2016;3(6):585–590.
117. Bousman CA, Forbes M, Jayaram M, et al. Antidepressant prescribing in the precision medicine era: a prescriber’s primer on pharmacogenetic tools. BMC Psychiatry. 2017;17(1):60.
118. Nassan M, Nicholson WT, Elliott MA, Rohrer Vitek CR, Black JL, Frye MA. Pharmacokinetic pharmacogenetic prescribing guidelines for antidepressants: a template for psychiatric precision medicine. Mayo Clin Proc. 2016;91(7):897–907.
119. Müller DJ, Kekin I, Kao AC, Brandl EJ. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. Int Rev Psychiatry. 2013;25(5):554–571.
120. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011;89(3):464–467.
121. Breitenstein B, Brückl TM, Ising M, Müller-Myhsok B, Holsboer F, Czamara D. ABCB1 gene variants and antidepressant treatment outcome: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2015;168B(4):274–283.
122. Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008;57(2):203–209.
123. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012;22(4): 239–258.
124. Meyer JH, Kapur S, Eisfeld B, et al. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry. 2001;158(1):78–85.
125. Pandey DK, Mahesh R, Kumar AA, Rao VS, Arjun M, Rajkumar R. A novel 5-HT(2A) receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants. Pharmacol Biochem Behav. 2010;94(3):363–373.
126. Winner JG, Dechairo B. Combinatorial versus individual gene pharmacogenomic testing in mental health: a perspective on context and implications on clinical utility. Yale J Biol Med. 2015;88(4): 375–382.
127. Berm EJ, Looff M, Wilffert B, et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PLoS One. 2016;11(1):e0146262.
128. Yu S-H, Liu S-K, Lin K-M. Psychopharmacology across cultures. In: Bhugra D, Bhui K, editors. Textbook of Cultural Psychiatry. 1st ed. Cambridge, UK: Cambridge University Press; 2007:402–413.
129. Menke A. Gene expression: biomarker of antidepressant therapy? Int Rev Psychiatry. 2013;25(5):579–591.
130. Gerhold DL, Jensen RV, Gullans SR. Better therapeutics through microarrays. Nat Genet. 2002;32(Suppl):547–551.
131. Dirven BCJ, Homberg JR, Kozicz T, Henckens M. Epigenetic programming of the neuroendocrine stress response by adult life stress. J Mol Endocrinol. 2017;59(1):R11–R31.
132. Reinbold CS, Forstner AJ, Hecker J, et al. Analysis of the influence of microRNAs in lithium response in bipolar disorder. Front Psychiatry. 2018;9:207.
133. Lopez JP, Kos A, Turecki G. Major depression and its treatment: microRNAs as peripheral biomarkers of diagnosis and treatment response. Curr Opin Psychiatry. 2018;31(1):7–16.
134. Mehta D, Gonik M, Klengel T, et al. Using polymorphisms in FKBP5 to define biologically distinct subtypes of posttraumatic stress disorder: evidence from endocrine and gene expression studies. Arch Gen Psychiatry. 2011;68(9):901–910.
135. Arloth J, Bogdan R, Weber P, et al. Genetic differences in the immediate transcriptome response to stress predict risk-related brain function and psychiatric disorders. Neuron. 2015;86(5):1189–1202.
136. Zannas AS, Arloth J, Carrillo-Roa T, et al. Lifetime stress accelerates epigenetic aging in an urban, African American cohort: relevance of glucocorticoid signaling. Genome Biol. 2015;16:266.
137. Shickel B, Tighe PJ, Bihorac A, Rashidi P. Deep EHR: a survey of recent advances in deep learning techniques for electronic health record (EHR) analysis. IEEE J Biomed Health Inform. 2018;22(5):1589–1604.
138. Pham T, Tran T, Phung D, Venkatesh S. Predicting healthcare trajectories from medical records: a deep learning approach. J Biomed Inform. 2017;69:218–229.
139. Tran T, Kavuluru R. Predicting mental conditions based on “history of present illness” in psychiatric notes with deep neural networks. J Biomed Inform. 2017;75S:S138–S148.
140. Rosenstein M, Foltz PW, Delisi LE, Elvevåg B. Language as a biomarker in those at high-risk for psychosis. Schizophr Res. 2015;165(2–3): 249–250.
141. Ebner-Priemer UW, Trull TJ. Ecological momentary assessment of mood disorders and mood dysregulation. Psychol Assess. 2009;21(4):463–475.
142. Kingslake J, Dias R, Dawson GR, et al. The effects of using the PReDicT test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial. Trials. 2017;18(1):558.
143. Surguladze SA, Young AW, Senior C, Brébion G, Travis MJ, Phillips ML. Recognition accuracy and response bias to happy and sad facial expressions in patients with major depression. Neuropsychology. 2004;18(2):212–218.
144. Harmer CJ, O’Sullivan U, Favaron E, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry. 2009;166(10):1178–1184.
145. Dawson GR, Dourish C, Kingslake J, Harmer C, Goodwin G, Browning M. A precision medicine approach to antidepressant treatment in depression. Eur Neuropsychopharmacol. 2015;25:S441.
146. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(10):718–779.
147. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30(14): 1663–1669.
148. Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med. 2005;352(24):2515–2523.
149. Wong EH, Yocca F, Smith MA, Lee CM. Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters’ perspective. Int J Neuropsychopharmacol. 2010;13(9):1269–1284.
150. Hofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A. The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cognit Ther Res. 2012;36(5):427–440.
151. Gabrieli JDE, Ghosh SS, Whitfield-Gabrieli S. Prediction as a humanitarian and pragmatic contribution from human cognitive neuroscience. Neuron. 2015;85(1):11–26.
152. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013;381(9875):1371–1379.
153. Ehrenreich H, Mitjans M, Van der Auwera S, et al. OTTO: a new strategy to extract mental disease-relevant combinations of GWAS hits from individuals. Mol Psychiatry. 2018;23(2):476–486.
154. Wolfers T, Buitelaar JK, Beckmann CF, Franke B, Marquand AF. From estimating activation locality to predicting disorder: a review of pattern recognition for neuroimaging-based psychiatric diagnostics. Neurosci Biobehav Rev. 2015;57:328–349.
155. Chan MK, Gottschalk MG, Haenisch F, et al. Applications of blood-based protein biomarker strategies in the study of psychiatric disorders. Prog Neurobiol. 2014;122:45–72.
156. Fu CH, Costafreda SG. Neuroimaging-based biomarkers in psychiatry: clinical opportunities of a paradigm shift. Can J Psychiatry. 2013;58(9):499–508.
157. Hofmann-Apitius M, Ball G, Gebel S, et al. Bioinformatics mining and modeling methods for the identification of disease mechanisms in neurodegenerative disorders. Int J Mol Sci. 2015;16(12):29179–29206.
158. Savitz JB, Rauch SL, Drevets WC. Clinical application of brain imaging for the diagnosis of mood disorders: the current state of play. Mol Psychiatry. 2013;18(5):528–539.
159. Scarr E, Millan MJ, Bahn S, et al. Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank. Int J Neuropsychopharmacol. 2015;18(10):pyv042.
160. Veronese E, Castellani U, Peruzzo D, Bellani M, Brambilla P. Machine learning approaches: from theory to application in schizophrenia. Comput Math Methods Med. 2013;2013:867924.
161. Hahn T, Nierenberg AA, Whitfield-Gabrieli S. Predictive analytics in mental health: applications, guidelines, challenges and perspectives. Mol Psychiatry. 2017;22(1):37–43.
162. Bzdok D, Meyer-Lindenberg A. Machine learning for precision psychiatry: opportunities and challenges. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3(3):223–230.
163. Woo CW, Chang LJ, Lindquist MA, Wager TD. Building better biomarkers: brain models in translational neuroimaging. Nat Neurosci. 2017;20(3):365–377.
164. Esteva A, Kuprel B, Novoa RA, et al. Dermatologist-level classif ication of skin cancer with deep neural networks. Nature. 2017;542(7639):115–118.
165. Kessler RC, van Loo HM, Wardenaar KJ, et al. Testing a machine-learning algorithm to predict the persistence and severity of major depressive disorder from baseline self-reports. Mol Psychiatry. 2016;21(10):1366–1371.
166. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2018;23(6):1241–1250.
167. Torkamani A, Andersen KG, Steinhubl SR, Topol EJ. High-definition medicine. Cell. 2017;170(5):828–843.
168. Lin E, Kuo PH, Liu YL, Yu Y, Yang AC, Tsai SJ. A deep learning approach for predicting antidepressant response in major depression using clinical and genetic biomarkers. Front Psychiatry. 2018;9(290):290.